Dorsal hippocampal NMDA receptors mediate the interactive effects of arachidonylcyclopropylamide and MDMA/ecstasy on memory retrieval in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 66, Issue , 2016, Pages 41-47

  Ghaderi, Marzieh ^a   Rezayof, Ameneh ^b   Vousooghi, Nasim ^a   Zarrindast, Mohammad Reza ^a,c,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d INSTITUTE FOR RESEARCH IN FUNDAMENTAL SCIENCES IPM   (Iran)

Author keywords

ACPA; Dorsal hippocampal NMDA receptors; MDMA; Memory formation; Rat(s)

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMIDE; ARACHIDONYLCYCLOPROPYLAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; 2 AMINO 5 PHOSPHONOVALERIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; ARACHIDONIC ACID DERIVATIVE; MIDOMAFETAMINE;

ADULT; AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DOSE RESPONSE; HIPPOCAMPAL CA1 REGION; HISTOPATHOLOGY; LATENT PERIOD; MALE; MEMORY; MEMORY DISORDER; NONHUMAN; PASSIVE AVOIDANCE TEST; RAT; TASK PERFORMANCE; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG INTERACTION; HIPPOCAMPUS; RECALL; WISTAR RAT;

2-AMINO-5-PHOSPHONOVALERATE; ANIMALS; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; MALE; MEMORY; MENTAL RECALL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84947968553     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.11.008     Document Type: Article

References (75)

1. Aberg M., Wade D., Wall E., Izenwasser S. Effect of MDMA (ecstasy) on activity and cocaine conditioned place preference in adult and adolescent rats. Neurotoxicol. Teratol. 2007, 29:37-46.
2. Adori C., Low P., Andó R.D., Gutknecht L., Pap D., Truszka F., Takács J., Kovács G., Lesch K.P., Bagdy G. Ultrastructural characterization of tryptophan hydroxylase 2-specific cortical serotonergic fibers and dorsal raphe neuronal cell bodies after MDMA treatment in rat. Psychopharmacology 2011, 213(2-3):377-391.
3. Alijanpour S., Rezayof A., Zarrindast M.R. Dorsal hippocampal cannabinoid CB1 receptors mediate the interactive effects of nicotine and ethanol on passive avoidance learning in mice. Addict. Biol. 2013, 18(2):241-251.
4. Almeida-Suhett C.P., Prager E.M., Pidoplichko V., Figueiredo T.H., Marini A.M., Li Z., Eiden L.E., Braga M.F. GABAergic interneuronal loss and reduced inhibitory synaptic transmission in the hippocampal CA1 region after mild traumatic brain injury. Exp. Neurol. 2015, 273:11-23.
5. Anneken J.H., Cunningham J.I., Collins S.A., Yamamoto B.K., Gudelsky G.A. MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase. Neuroimmune Pharmacol. 2013, 8(1):58-65.
6. Anneken J.H., Gudelsky G.A. MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus. Neuropharmacology 2012, 63(6):1022-1027.
7. Basavarajappa B.S., Nagre N.N., Xie S., Subbanna S. Elevation of endogenous anandamide impairs LTP, learning, and memory through CB1 receptor signaling in mice. Hippocampus 2014, 24(7):808-818.
8. Broening H.W., Morford L.L., Inman-Wood S.L., Fukumura M., Vorhees C.V. 3,4- methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J. Neurosci. 2001, 21:3228-3235.
9. Capela J.P., Carmo H., Remião F., Bastos M.L., Meisel A., Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol. 2009, 39(3):210-271.
10. Chipana C., Torres I., Camarasa J., Pubill D., Escubedo E. Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. Neuropharmacology 2008, 54:1254-1263.
11. Clay S.W., Allen J., Parran T. A review of addiction. Postgrad. Med. 2008, 120(2):E01-E07.
12. Demuth D.G., Molleman A. Cannabinoid signaling. Life Sci. 2006, 78(6):549-563.
13. Domenici M.R., Azad S.C., Marsicano G., Schierloh A., Wotjak C.T., Dodt H.U., Zieglgänsberger W., Lutz B., Rammes G. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J. Neurosci. 2006, 26(21):5794-5799.
14. Dumont G., Van Hasselt J., de Kam M., van Gerven J.M., Touw D.J., Buitelaar J.K., Verkes R.J. Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers. J. Psychopharmacol. 2011, 25(4):478-489.
15. Eisch A.J., Harburg G.C. Opiates, psychostimulants, and adult hippocampal neurogenesis: insights for addiction and stem cell biology. Hippocampus 2006, 16(3):271-286.
16. 1 cannabinoid receptors control frontocortical serotonin and glutamate release - species differences. Neurochem. Int. 2012, 61(2):219-226.
17. García-Pardo M.P., Escobar-Valero C., Rodríguez-Arias M., Miñarro J., Aguilar M.A. Involvement of NMDA glutamate receptors in the acquisition and reinstatement of the conditioned place preference induced by MDMA. Behav. Pharmacol. 2015, 26(5):411-417.
18. Gessa G.L., Casu M.A., Carta G., Mascia M.S. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. Eur. J. Pharmacol. 1997, 355(2-3):119-124.
19. Ghiasvand M., Rezayof A., Zarrindast M.R., Ahmadi S. Activation of cannabinoid CB1 receptors in the central amygdala impairs inhibitory avoidance memory consolidation via NMDA receptors. Neurobiol. Learn. Mem. 2011, 96(2):333-338.
20. Gouzoulis-Mayfrank E., Daumann J., Tuchtenhagen F., Pelz S., Becker S., Kunert H.J., Fimm B., Sass H. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J. Neurol. Neurosurg. Psychiatry 2000, 68(6):719-725.
21. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3,4- methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem. 1996, 66:243-249.
22. Gudelsky G.A., Yamamoto B.K. Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol. Biochem. Behav. 2008, 90(2):198-207.
23. Han J., Kesner P., Metna-Laurent M., Duan T., Xu L., Georges F., Koehl M., Abrous D.N., Mendizabal-Zubiaga J., Grandes P., Liu Q., Bai G., Wang W., Xiong L., Ren W., Marsicano G., Zhang X. Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 2012, 148(5):1039-1050.
24. Hasler F., Studerus E., Lindner K., Ludewig S., Vollenweider F.X. Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. J. Psychopharmacol. 2009, 23:923-935.
25. Iversen L. Cannabis and the brain. Breain 2003, 126(Pt 6):1252-1270.
26. Izquierdo I., Medina J.H., Vianna M.R., Izquierdo L.A., Barros D.M. Separate mechanisms for short- and long-term memory. Behav. Brain Res. 1999, 103(1):1-11.
27. Kawamura Y., Fukaya M., Maejima T., Yoshida T., Miura E., Watanabe M., Ohno-Shosaku T., Kano M. The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J. Neurosci. 2006, 26(11):2991-3001.
28. Kindlundh-Högberg A.M., Blomqvist A., Malki R., Schiöth H.B. Extensive neuroadaptive changes in cortical gene-transcript expressions of the glutamate system in response to repeated intermittent MDMA administration in adolescent rats. BMC Neurosci. 2008, 9:39.
29. Lichtman A.H., Dimen K.R., Martin B.R. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 1995, 119(3):282-290.
30. Lichtman A.H., Varvel S.A., Martin B.R. Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 2002, 66(2-3):269-285.
31. Maier N., Morris G., Schuchmann S., Korotkova T., Ponomarenko A., Böhm C., Wozny C., Schmitz D. Cannabinoids disrupt hippocampal sharp wave-ripples via inhibition of glutamate release. Hippocampus 2012, 22(6):1350-1362.
32. Maldonado E., Navarro J.F. Effects of 3,4- methylenedioxymethamphetamine (MDMA) on anxiety in mice tested in the light-dark box. Prog. Neuro. Psychopharmacol. Biol. Psychiatry 2000, 24:463-472.
33. McAleer L.M., Schallert T., Duvauchelle C.L. Weekend ecstasy use disrupts memory in rats. Neurosci. Lett. 2013, 549:173-176.
34. McHugh S.B., Niewoehner B., Rawlins J.N., Bannerman D.M. Dorsal hippocampal N-methyl-D-aspartate receptors underlie spatial working memory performance during non-matching to place testing on the T-maze. Behav. Brain Res. 2008, 186(1):41-47.
35. Melis M., Pistis M., Perra S., Muntoni A.L., Pillolla G., Gessa G.L. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci. 2004, 24(1):53-62.
36. Milani R.M., Parrott A.C., Schifano F., Turner J.J. Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms. Hum. Psychopharmacol. 2005, 20(4):249-261.
37. Morley K.C., Li K.M., Hunt G.E., Mallet P.E., McGregor I.S. Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ('ecstasy') in rats. Neuropharmacology 2004, 46:954-965.
38. Moyano S., Frechilla D., Del Río J. NMDA receptor subunit and CaMKII changes in rat hippocampus induced by acute MDMA treatment: a mechanism for learning impairment. Psychopharmacology 2004, 173(3-4):337-345.
39. Mueller M., Maldonado-Adrian C., Yuan J., McCann U.D., Ricaute G.A. Studies of (±)-3,4-methylenedioxymethamphetamine (MDMA) metabolism and disposition in rats and mice: relationship to neuroprotection and neurotoxicity profile. J. Pharmacol. Exp. Ther. 2013, 344(2):479-488.
40. Nawata Y., Hiranita T., Yamamoto T. A cannabinoid CB(1) receptor antagonist ameliorates impairment of recognition memory on withdrawal from MDMA (ecstasy). Neuropsychopharmacology 2010, 35(2):515-520.
41. Nazari-Serenjeh F., Rezayof A. Cooperative interaction between the basolateral amygdala and ventral tegmental area modulates the consolidation of inhibitory avoidance memory. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 40:54-61.
42. Parrot A.C. MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation. Br. J. Pharmacol. 2012, 166(5):1518-1520.
43. Parrott A.C. Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: cognitive an behavioral indices of change. Neuropsychobiology 2000, 42:17-24.
44. Parrott A.C., Gouzoulis E., Rodgers J., Solowij N. Ecstasy/MDMA and cannabis: the complexities of their interactive neuropsychobiological effects. J. Psychopharmacol. 2004, 18(4):572-575.
45. Paxinos G., Watson C. The rat brain in stereotaxic coordinates, 3rd edn. San Diego: academic press. Psychopharmacology 2007, 189:489-503.
46. Rasekhi K., Oryan S., Nasehi M., Zarrindast M.R. Involvement of the nucleus accumbens shell glutamatergic system in ACPA-induced impairment of inhibitory avoidance memory consolidation. Behav. Brain Res. 2014, 269:28-36.
47. Rey A.A., Purrio M., Viveros M.P., Lutz B. Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 2012, 37(12):2624-2634.
48. Rezayof A., Habibi P., Zarrindast M.R. Involvement of dopaminergic and glutamatergic systems of the basolateral amygdala in amnesia induced by the stimulation of dorsal hippocampal cannabinoid receptors. Neuroscience 2011, 175:118-126.
49. Ricaurte G.A., Yuan J., McCann U.D. (±)3,4-methylenedioxymethamphetamine ("ecstasy")-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 2000, 42:5-10.
50. Riezzo I., Cerretani D., Fiore C., Bello S., Centini F., D'Errico S., Fiaschi A.I., Giorgi G., Neri M., Pomara C., Turillazzi E., Fineschi V. Enzymatic-nonenzymatic cellular antioxidant defense systems response and immunohistochemical detection of MDMA, VMAT2, HSP70, and apoptosis as biomarkers. J. Neurosci. Res. 2010, 88(4):905-916.
51. Riegert C., Wedekind F., Hamida S.B., Rutz S., Rothmaier A.K., Jones B.C., Cassel J.C., Jackisch R. Effects of ethanol and 3,4-methylenedioxymethamphetamine (MDMA) alone or in combination on spontaneous and evoked overflow of dopamine, serotonin and acetylcholine in striatal slices of the rat brain. Int. J. Neuropsychopharmacol. 2008, 11(6):743-763.
52. Sala M., Braida D. Endocannabinoids and 3,4- ethylenedioxymethamphetamine (MDMA) interaction. Pharmacol. Biochem. Behav. 2005, 81:407-416.
53. Sanchez V., Camarero J., Esteban B., PeterMJ G.A.R., Colado M.I. The mechanisms involved in the long lasting neuroprotective effect of fluoxetine against MDMA induced degeneration of 5-HT nerve endings in rat brain. Br. J. Pharmacol. 2001, 134:46-57.
54. Sarter M., Hagan J., Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part I. Psychopharmacology 1992, 107(2-3):144-159.
55. Schilt T., de Win M.M., Jager G., Koeter M.W., Ramsey N.F., Schmand B., van den Brik W. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users. Psychol. Med. 2008, 38:1309-1317.
56. Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 2001, 22:565-572.
57. Schulz S. MDMA & cannabis: a mini-review of cognitive, behavioral, and neurobiological effects of co-consumption. Curr. Drug Abuse Rev. 2011, 4(2):81-86.
58. Schulz S., Becker T., Nagel U., von Ameln-Mayerhofer A., Koch M. Chronic co-administration of the cannabinoid receptor agonist WIN55,212-2 during puberty or adulthood reverses 3,4 methylenedioxymethamphetamine (MDMA)-induced deficits in recognition memory but not in effort-based decision making. Pharmacol. Biochem. Behav. 2013, 106:91-100.
59. Shariati M.B., Sohrabi M., Shahidi S., Nikkhah A., Mirzaei F., Medizadeh M., Asl S.S. Acute effects of ecstasy on memory are more extensive than chronic effects. Basic Clin. Neurosci. 2014, 5(3):225-230.
60. Sprague J.E., Banks M.L., Cook V.J., Mills E.M. Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in the hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). J. Pharmacol. Exp. Ther. 2003, 305(1):159-166.
61. Suenaga T., Ichitani Y. Effects of hippocampal administration of a cannabinoid receptor agonist WIN 55,212-2 on spontaneous object and place recognition in rats. Behav. Brain Res. 2008, 190(2):248-252.
62. Suenaga T., Kaku M., Ichitani Y. Effects of intrahippocampal cannabinoid receptor agonist an antagonist on radial maze and T-maze delayed alternation performance in rats. Pharmacol. Biochem. Behav. 2008, 91(1):91-96.
63. Taffe M.A., Davis S.D., Yuan J., Schroeder R., Hatzidimitriou G., Parsons L.H., Ricaurte G.A., Gold L.H. Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to serotonergic challenge. Neuropsychopharmacology 2002, 27(6):993-1005.
64. Terranova J.P., Michaud J.C., Le Fur G., Soubrie P. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn Schmiedeberg's Arch. Pharmacol. 1995, 352:576-579.
65. Thomasius R., Petersen K., Buchert R., Andresen B., Zapletalova P., Artberg L., Nebeling B., Schmoldt A. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 2003, 167:85-96.
66. Tirgar F., Rezayof A., Zarrindast M.R. Central amygdala nicotinic and 5-HT1A receptors mediate the reversal effect of nicotine and MDMA on morphine-induced amnesia. Neuroscience 2014, 277:392-402.
67. Tizabi Y., Bai L., Copeland R.L., Taylor R.E. Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcohol. 2007, 42(5):413-416.
68. van Wel J.H., Kuypers K.P., Theunissen E.L., Bosker W.M., Bakker K. Blockade of 5-HT(2) receptor selectively prevents MDMA-induced verbal memory impairment. Neuropsychopharmacology 2011, 36:1932-1939.
69. Varnäs K., Halldin C., Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum. Brain Mapp. 2004, 22:246-260.
70. Venkatesan A., Nath A., Ming G.L., Song H. Adult hippocampal neurogenesis: regulation by HIV and drugs of abuse. Cell. Mol. Life Sci. 2007, 64:2120-2132.
71. Verkes R.J., Gijsman H.J., Pieters M.S., Schoemaker R.C., de Visser S., Kuijpers M., Pennings E.J., de Bruin D., Van de Wijngaart G., Van Gerven J.M., Cohen A.F. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 2001, 153:196-202.
72. Verrico C.D., Miller G.M., Madras B.K. MDMA and human dopamine, norepinephrine and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 2007, 189:489-503.
73. Vidal-Infer A., Roger-Sánchez C., Daza-Losada M., Aguilar M.A., Miñarro J., Rodríguez-Arias M. Role of the dopaminergic system in the acquisition, expression and reinstatement of MDMA-induced conditioned place preference in adolescent mice. PLoS One 2012, 7(8).
74. Yamada K., Shimizu M., Kawabe K., Ichitani Y. Hippocampal AP5 treatment impairs both spatial working and reference memory in radial maze performance in rats. Eur. J. Pharmacol. 2015, 758:137-141.
75. Zaretsky D.V., Zaretskaia M.V., Rusyniak D.E., Dimicco J.A. Stress-free microinjections in conscious rats. J. Neurosci. Methods 2011, 199(2):199-207.